Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 105

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 105
---
%$91,623 60 %$3,384 4 %R&D discovery costs21,043 13 %17,634 12 %3,409 19 %Salaries26,531 16 %24,532 16 %1,999 8 %Facilities related6,457 4 %7,132 4 %(675)(9)%Total research and development expense, excluding non-cash expense$149,038 91 %$140,921 92 %$8,117 6 %Stock compensation7,612 5 %7,241 5 %371 5 %Depreciation and amortization5,718 4 %4,269 3 %1,449 34 %Total research and development expense$162,368 100 %$152,431 100 %$9,937 7 %

(in thousands)Nine Months Ended June 30, 2025% ofExpenseCategory Nine Months Ended June 30, 2024% ofExpenseCategory Increase (Decrease)$%Candidate costs$243,094 56 %$185,708 50 %$57,386 31 %R&D discovery costs48,785 11 %56,736 15 %(7,951)(14)%Salaries80,583 19 %72,048 19 %8,535 12 %Facilities related20,944 5 %19,597 7 %1,347 7 %Total research and development expense, excluding non-cash expense$393,406 91 %$334,089 91 %$59,317 18 %Stock compensation23,049 5 %23,735 6 %(686)(3)%Depreciation and amortization16,017 4 %12,220 3 %3,797 31 %Total research and development expense$432,472 100 %$370,044 100 %$62,428 17 %

Candidate costs increased $3.4 million, or 4%, for the three months ended June 30, 2025 compared to the same period of 2024, and $57.4 million, or 31%, for the nine months ended June 30, 2025 compared to the same period of 2024. The